<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of kidney disease in patients with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of kidney disease in patients with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of kidney disease in patients with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christina M Wyatt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Klotman, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 14, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H31719887"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>With dramatic improvements in survival and disease progression in the era of combination antiretroviral therapy (ART), complications such as kidney, liver, and cardiac disease have largely replaced opportunistic infections as the leading causes of mortality in the setting of HIV [<a href="#rid1">1</a>]. Patients with HIV are at risk for both acute kidney injury (AKI) and chronic kidney disease (CKD) secondary to medication nephrotoxicity, HIV-associated nephropathy (HIVAN) [<a href="#rid2">2-5</a>], and immune complex kidney diseases [<a href="#rid5">5-9</a>]. In addition, the aging cohort of patients with HIV is at increased risk for comorbid kidney disease related to traditional CKD risk factors including diabetes, hypertension, and obesity, as well as kidney disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfection [<a href="#rid5">5,10,11</a>].</p><p class="headingAnchor" id="H31719894"><span class="h1">ACUTE KIDNEY INJURY</span></p><p class="headingAnchor" id="H15534502"><span class="h2">Epidemiology of AKI in patients with HIV</span></p><p class="headingAnchor" id="H15534676"><span class="h3">Incidence of AKI</span><span class="headingEndMark"> — </span>The incidence of acute kidney injury (AKI) is increased in patients with HIV compared with patients without HIV. Although the overall incidence of AKI in patients with HIV appears to be decreasing in the antiretroviral therapy (ART) era, the incidence of severe, dialysis-requiring AKI continues to rise.</p><p>In a study of hospitalized adults in New York state that compared administrative data from 1995 (before the introduction of ART) with data from 2003 (after the introduction of ART) [<a href="#rid12">12</a>], AKI was documented in a significantly greater proportion of patients with HIV compared with patients without HIV, both in 1995 (2.9 versus 1 percent) and 2003 (6 versus 2.7 percent). Because this study relied on administrative data to identify AKI cases, it is likely that only more severe cases were included.</p><p>Other studies have also demonstrated an increasing incidence of severe, dialysis-requiring AKI among hospitalized patients with HIV. In a study including more than 56,000 United States military veterans, the incidence of dialysis-requiring AKI declined early in the ART era but then doubled between 2000 and 2006 [<a href="#rid13">13</a>]. A similar increase in the incidence of dialysis-requiring AKI among adults with HIV was also demonstrated in a nationally representative sample of United States hospital admissions [<a href="#rid14">14</a>].</p><p>Two single-center cohort studies have evaluated the incidence and etiology of AKI among ambulatory patients engaged in HIV care in the ART era, using clinical and laboratory data to identify AKI cases [<a href="#rid15">15,16</a>]. In a prospective study of 754 ambulatory patients with HIV followed at a single center in the United States, at least one episode of AKI occurred in 71 patients (9.4 percent) during a two-year period [<a href="#rid15">15</a>]. In a retrospective study of more than 2200 patients with HIV engaged in care at a single center in London, AKI occurred in 5.7 percent of patients and was most common within the first three months of initiating HIV care [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H15534695"><span class="h3">Risk factors for AKI</span><span class="headingEndMark"> — </span>Some risk factors for acute kidney injury (AKI) among patients with HIV are similar to risk factors for AKI in the general population, such as older age, diabetes mellitus, preexisting chronic kidney disease (CKD), and acute or chronic liver disease [<a href="#rid12">12,14</a>]. However, some risk factors are specific to HIV. In studies that have included detailed data on HIV disease severity, other predictors of AKI included a diagnosis of AIDS, low CD4 count, high viral load, and coinfection with hepatitis C virus (HCV) [<a href="#rid13">13,15,16</a>].</p><p class="headingAnchor" id="H15534728"><span class="h3">Outcomes after AKI</span><span class="headingEndMark"> — </span>As in the general population, the development of acute kidney injury (AKI) increases the risk of morbidity and mortality in patients with HIV. The following examples illustrate an association with both short-term and long-term outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>Inpatient mortality was significantly more frequent among patients with HIV who had AKI than among patients with HIV without AKI in a 2003 sample of hospitalized patients in New York state (27 versus 4 percent) [<a href="#rid12">12</a>]. Dialysis-requiring AKI was also associated with a significantly increased risk of in-hospital mortality among adults with HIV in a nationally representative sample of United States hospital admissions from 2010 (adjusted odds ratio [OR] 2.64, 95% CI 2.04-3.42) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term mortality is also higher among individuals with HIV who develop AKI. In a national sample of United States military veterans from 1986 through 2006, 17,325 veterans with HIV were hospitalized and survived for at least 90 days after discharge [<a href="#rid17">17</a>]. AKI occurred in 3060 (18 percent); 334 of these patients with AKI also required dialysis. During an average follow-up of 5.7 years after hospital discharge, the patients with HIV who experienced AKI were significantly more likely to die (56 versus 47 percent). End-stage kidney disease (ESKD) and cardiovascular events were also significantly more common among patients with HIV with AKI.</p><p></p><p class="headingAnchor" id="H15534510"><span class="h2">Causes of AKI in patients with HIV</span><span class="headingEndMark"> — </span>Prior to the introduction of combination ART, acute kidney injury (AKI) was commonly attributed to septicemia, volume depletion, or medication toxicity [<a href="#rid18">18,19</a>]. Although data on the etiology of AKI in the ART era are limited, available data suggest that sepsis remains a common contributor and that AKI is often multifactorial [<a href="#rid14">14-16</a>]. The most common types of AKI in patients with HIV infection, similar to patients without HIV, are prerenal states and acute tubular necrosis. Causes of AKI that are unique to patients with HIV are discussed in this section. (See  <a class="medical medical_review" href="/z/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults"</a>.)</p><p class="headingAnchor" id="H31719901"><span class="h3">Medication nephrotoxicity</span><span class="headingEndMark"> — </span>Patients with HIV infection are at risk for nephrotoxicity from ART, as well as from medications used to treat opportunistic infections or hepatitis virus coinfection. In addition, ART-treated patients are often taking additional medications for the treatment of comorbid conditions. Medication nephrotoxicity may present with acute or chronic kidney injury or with acid-base and electrolyte disturbances. (See <a class="local">'Chronic kidney disease'</a> below and <a class="local">'Electrolyte disorders'</a> below.)</p><p>Some of the more commonly implicated agents include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">Tenofovir disoproxil fumarate</a> (TDF) – Tenofovir is a nucleotide reverse transcriptase inhibitor. TDF is a prodrug of tenofovir that can cause AKI, proximal tubular dysfunction, or both in combination. The use of TDF has also been associated with increased risk of CKD in large observational studies [<a href="#rid20">20-22</a>] (see <a class="local">'Epidemiology of CKD in patients with HIV'</a> below). In addition, the benefits of ART on proteinuria and albuminuria may be less substantial with regimens containing TDF as compared with the alternative nucleoside reverse transcriptase inhibitor, <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> [<a href="#rid23">23</a>]. According to expert guidelines, TDF should be avoided, if feasible, in patients with an estimated glomerular filtration rate (eGFR) less than 60 mL/min per 1.73 m<sup>2</sup> and should be discontinued in patients who experience a 25 percent or greater decline to an eGFR less than 60 mL/min per 1.73 m<sup>2</sup> [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent1">The risk of kidney toxicity with TDF has varied across different studies, with estimates ranging from less than 2 percent to as high as 10 percent in one study [<a href="#rid26">26,27</a>]. Although kidney biopsy may not be necessary to diagnose TDF toxicity in the setting of proximal tubular dysfunction, it can be useful in cases where the diagnosis is less clear or where there are compelling reasons not to discontinue TDF. As an example, in a French study of 222 patients with HIV infection who underwent kidney biopsy, 29 had tubulopathy (13 percent); TDF was considered a primary or secondary contributing factor in nearly two-thirds of these cases [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">A newer prodrug, <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF), was approved in 2015 based upon studies demonstrating the potential for an improved safety profile. TAF achieves similar antiviral efficacy at much lower plasma concentrations of tenofovir, and randomized trials have demonstrated a significantly smaller decline in eGFR over 96 weeks in patients treated with a TAF-containing regimen compared with those treated with a TDF-containing regimen [<a href="#rid29">29</a>]. Although TAF is expected to result in a lower risk of clinically relevant kidney toxicity compared with TDF-containing regimens, AKI has been reported with TAF use [<a href="#rid30">30,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protease inhibitors – <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">Indinavir</a> and <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> are protease inhibitors that can cause crystalluria, nephrolithiasis, and AKI. The use of some ritonavir-boosted protease inhibitors has also been associated with increased risk of CKD in large observational studies [<a href="#rid20">20-22</a>]; of note, the newer protease inhibitor <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a> does not appear to be associated with an increased risk of CKD [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury", section on 'Protease inhibitors'</a> and <a class="local">'Epidemiology of CKD in patients with HIV'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other antiviral agents – <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">Acyclovir</a>, <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>, and <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> are drugs used to treat herpes simplex virus or cytomegalovirus infection. Each of these agents can be associated with the development of AKI. (See  <a class="medical medical_review" href="/z/d/html/7229.html" rel="external">"Crystal-induced acute kidney injury", section on 'Acyclovir'</a> and  <a class="medical medical_review" href="/z/d/html/8288.html" rel="external">"Foscarnet: An overview", section on 'Renal insufficiency'</a> and  <a class="medical medical_review" href="/z/d/html/8297.html" rel="external">"Cidofovir: An overview", section on 'Toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-<em>Pneumocystis</em> drugs – <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> and, less commonly, <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a> are agents used to treat <em>Pneumocystis</em> infection. Trimethoprim-sulfamethoxazole can produce interstitial nephritis, while approximately 25 percent of patients treated with pentamidine develop reversible AKI that is likely due to nephrotoxic acute tubular necrosis [<a href="#rid17">17,33-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Drugs'</a>.)</p><p></p><p>In addition, several antiretroviral agents can interfere with the tubular secretion of creatinine, producing an increase in serum creatinine (and decline in eGFR) without a true decline in kidney function. The most prominent effect has been observed with the pharmacoenhancer <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a> and the integrase inhibitor <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a>; the increase in serum creatinine with these drugs occurs early and is typically in the range of 0.05 to 0.2 mg/dL [<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H966867"><span class="h3">HIV-associated kidney disease</span><span class="headingEndMark"> — </span>HIV-associated nephropathy (HIVAN), HIV immune complex kidney disease (HIVICK), and HIV-associated thrombotic microangiopathy can all present with AKI (see  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a> and <a class="local">'Causes of CKD in patients with HIV'</a> below). While HIV-associated thrombotic microangiopathy can present with significant AKI [<a href="#rid38">38,39</a>], results of a large observational cohort study suggest that this is a rare complication of HIV infection in the ART era [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H31719915"><span class="h1">CHRONIC KIDNEY DISEASE</span></p><p class="headingAnchor" id="H15534518"><span class="h2">Epidemiology of CKD in patients with HIV</span><span class="headingEndMark"> — </span>The prevalence and incidence of chronic kidney disease (CKD) are higher in individuals with HIV than in the general population. With earlier introduction of effective antiretroviral therapy (ART), the incidence of HIV-related end-stage kidney disease (ESKD) has decreased [<a href="#rid41">41</a>].</p><p>The prevalence of CKD associated with HIV infection varies according to the population studied; the following examples illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort of 2059 women with HIV followed in the Women's Interagency HIV Study (WIHS) both before and after the introduction of combination ART, nearly one-third of 2059 subjects had persistent proteinuria at enrollment [<a href="#rid34">34</a>]. Advanced HIV infection was associated with both baseline proteinuria and the development of acute or chronic kidney disease in this cohort.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort of 22,156 military veterans with HIV followed for eight years, 27 patients (0.1 percent) had proteinuria greater than 300 mg/day at baseline, and 51 patients (0.2 percent) had an estimated glomerular filtration rate (eGFR) less than 60 mL/min per 1.73 m<sup>2</sup> at baseline [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional analysis of 783 men with HIV in the prospective Multicenter AIDS Cohort Study (MACS), 5 to 7 percent had an eGFR less than 60 mL/min per 1.73 m<sup>2</sup>, depending upon the method used to estimate GFR [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional study of 300 patients with HIV from the East African Republic of Burundi, only 2 percent had an eGFR less than 60 mL/min per 1.73 m<sup>2 </sup>[<a href="#rid44">44</a>], although persistent urinary abnormalities (principally, persistent pyuria) were much more common. By contrast, in a cross-sectional study of 400 adults with HIV from the West African nation of Nigeria, 38 percent had a persistently abnormal serum creatinine (&gt;1.5 mg/dL) and/or proteinuria [<a href="#rid45">45</a>]. The prevalence of CKD among individuals with HIV varies significantly across different studies and different populations in sub-Saharan Africa, reflecting significant variability in genetic susceptibility to HIV-associated nephropathy (HIVAN) and other kidney diseases conferred by polymorphisms in the <em>APOL1</em> gene [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a large, multinational, randomized trial enrolling ART-naïve participants with a CD4 cell count &gt;500 cells/microL, the baseline prevalence of CKD, defined as an eGFR less than 60 mL/min per 1.73 m<sup>2</sup> or the presence of dipstick proteinuria, was only 6.2 percent [<a href="#rid47">47</a>]. The majority of participants with CKD had isolated proteinuria. Although the observed prevalence of CKD was low, it was higher than expected given the young age distribution of the patient population.</p><p></p><p>Risk factors for incident or progressive CKD in adults with HIV include hepatitis C virus (HCV) coinfection, low CD4 cell count, high HIV viral load, and traditional CKD risk factors such as diabetes and hypertension. Treatment with <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF) and boosted protease inhibitors has also been associated with glomerular filtration rate (GFR) decline or decreased GFR in several studies, while ART in general appears to slow the rate of kidney function decline. The following studies provide examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In the prospective cohort of 22,156 military veterans described above, ESKD developed in 366 patients (1.7 percent) [<a href="#rid42">42</a>]. Patients who developed ESKD were more likely to have hypertension, diabetes, cardiovascular disease, HCV coinfection, low CD4 cell count, and high HIV viral load.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 8235 European adults with HIV enrolled in a prospective cohort, the incidence of CKD, defined as an eGFR persistently below 60 mL/min per 1.73 m<sup>2</sup>, was 6 percent [<a href="#rid48">48</a>]. Older age, an AIDS diagnosis, and coinfection with HCV were independent predictors of CKD. HCV viremia was independently associated with CKD in this cohort and with CKD progression in a secondary analysis of two international HIV treatment trials [<a href="#rid49">49</a>]. By contrast, HCV antibody status was associated with CKD risk regardless of HCV viremia in an analysis from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), a consortium of North American HIV cohorts [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective cohort of 3329 patients who initiated ART under routine clinical care, ART initiation significantly slowed the rate of eGFR decline over a median follow-up of 4.8 years (eGFR loss of 1.4 after versus 2.2 mL/min per 1.73 m<sup>2</sup> per year before initiation) [<a href="#rid51">51</a>]. The incidence of CKD was 3.2 percent; the risk was higher among Black individuals and those with HCV coinfection, lower CD4 cell count, higher HIV viral load, an AIDS diagnosis, and hypertension. The combination of TDF with a boosted protease inhibitor was also associated with a significant increase in the risk of developing an eGFR below 60 mL/min per 1.73 m<sup>2</sup> but not below 30 mL/min per 1.73 m<sup>2</sup>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several other large cohort studies have also demonstrated an association between exposure to TDF and/or ritonavir-boosted protease inhibitors and moderately decreased GFR [<a href="#rid20">20-22</a>]. In a large European cohort, use of TDF or ritonavir-boosted <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> was associated with an eGFR below 70 mL/min per 1.73 m<sup>2</sup> but not with an eGFR below 30 mL/min per 1.73 m<sup>2 </sup>[<a href="#rid22">22</a>]. The authors speculated that a high rate of TDF discontinuation among those with low GFR may have prevented further GFR decline. Of note, ritonavir-boosted <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a>, a newer protease inhibitor, does not appear to be associated with an increased risk of CKD [<a href="#rid32">32</a>]. Previous studies have not considered the use of <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a> as an alternative pharmacoenhancer.</p><p></p><p class="bulletIndent1">Kidney disease risk scores have been derived in United States military veterans with HIV and in a large European cohort of ART-treated individuals [<a href="#rid52">52,53</a>] and could be used to identify individuals at highest risk.</p><p></p><p class="headingAnchor" id="H15534526"><span class="h2">Causes of CKD in patients with HIV</span><span class="headingEndMark"> — </span>The etiology of CKD in patients with HIV includes both traditional CKD risk factors such as hypertension, diabetes, obesity, and incomplete recovery from an episode of acute kidney injury (AKI), as well as HIV-related disorders, including HIVAN and immune complex kidney disease. In addition, individuals with viral hepatitis coinfection are also at risk for glomerulonephritis secondary to hepatitis B virus (HBV) or HCV.</p><p class="headingAnchor" id="H31719922"><span class="h3">HIV-associated nephropathy</span><span class="headingEndMark"> — </span>The classic kidney disease of HIV infection, HIVAN, was first described in 1984 in patients with advanced HIV infection. (See  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a>.)</p><p>HIVAN is a collapsing form of focal segmental glomerulosclerosis (FSGS) with associated tubular microcysts and interstitial inflammation. HIVAN classically presents with significant proteinuria and rapidly progressive kidney disease in the setting of normal blood pressure and normal to enlarged kidneys, although the presentation may be less dramatic in the ART era. The pathogenesis, clinical manifestations, diagnosis, and treatment of HIVAN are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a>.)</p><p class="headingAnchor" id="H31719929"><span class="h3">Immune complex kidney disease</span><span class="headingEndMark"> — </span>A large proportion of patients with HIV who have proteinuric kidney disease and suspected HIVAN will have an alternative diagnosis on biopsy [<a href="#rid5">5</a>]. A number of immune complex kidney diseases have been reported in patients with HIV infection, including membranous nephropathy, membranoproliferative and mesangial proliferative glomerulonephritis, "lupus-like" proliferative glomerulonephritis, and immunoglobulin A (IgA) nephropathy [<a href="#rid5">5-9,54</a>]. In addition, a unique immune complex kidney disease with a characteristic "ball in cup" basement membrane reaction was described in a South African biopsy series [<a href="#rid55">55</a>]. The pathogenic relationship between HIV infection and the development of immune complex kidney diseases has not been extensively studied, although a role for viral antigens in circulating immune complexes and deposits has been suggested [<a href="#rid7">7,56</a>].</p><p>The natural history and response of immune complex kidney disease to ART have not been well described; the clinical course may vary depending upon the specific immune complex disease. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study including 751 patients with HIV, those with immune complex kidney disease were predominantly Black patients, and most had advanced HIV disease [<a href="#rid57">57</a>]. The incidence of ESKD in such patients was 32 percent at two years, much lower than that observed in the patients with HIVAN. ART was not associated with improved kidney disease outcomes in patients with immune complex kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small series of four patients with HIV-associated IgA nephropathy, the kidney disease followed a benign course similar to that observed in the absence of HIV [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective cohort including 42 patients with biopsy-proven HIVAN and 47 patients with alternative histologic diagnoses, Black patients and those with more advanced HIV infection had a higher risk for HIVAN. In addition, there was no evidence of a beneficial role for ART in non-HIVAN kidney diseases, which were associated with slower progression to ESKD regardless of therapy [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small retrospective study suggests a more aggressive course in patients with immune complex kidney disease resembling lupus glomerulonephritis [<a href="#rid59">59</a>]. In this cohort, 10 of 14 patients progressed to ESKD within one year.</p><p></p><p>Because the clinical course and response to ART appear to vary across different types of immune complex kidney disease in the setting of HIV infection, it is recommended that these cases be classified and managed based upon the primary histologic lesion [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H31719936"><span class="h3">Glomerulonephritis due to hepatitis C virus coinfection</span><span class="headingEndMark"> — </span>HCV coinfection has been associated with the development of acute and chronic kidney disease in large cohort studies of patients with HIV [<a href="#rid12">12,15,34,48,51</a>]. However, the histologic patterns of kidney disease have not been studied in large populations of coinfected patients. Membranoproliferative glomerulonephritis (MPGN) is strongly associated with HCV infection in the general population and is a common alternative diagnosis in coinfected patients [<a href="#rid5">5,10,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a>.)</p><p>Treatment of HCV-associated MPGN in the setting of HIV coinfection has not been rigorously studied. With the availability of effective and well-tolerated direct-acting antiviral therapy for HCV, treatment of the underlying HCV infection is now feasible in these cases. (See  <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/3070.html" rel="external">"Mixed cryoglobulinemia syndrome: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>.)</p><p class="headingAnchor" id="H31719950"><span class="h2">Diagnosis and management of CKD in patients with HIV</span><span class="headingEndMark"> — </span>We agree with expert guidelines that recommend screening and early identification of chronic kidney disease (CKD) in patients with HIV [<a href="#rid24">24,25</a>]. Individuals with HIV should have their GFR estimated at least twice yearly and should have either a urinalysis or quantitative assessment of urine protein excretion at least once yearly in order to monitor for the development of kidney disease. Such patients whose eGFR has declined by 25 percent or more to a level below 60 mL/min per 1.73 m<sup>2</sup>, or who have protein excretion greater than 300 mg/day, should be referred for nephrology evaluation.</p><p>GFR should be estimated using a creatinine-based estimate; available data do not support the use of cystatin C alone to estimate GFR in adults with HIV [<a href="#rid60">60,61</a>]. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) GFR estimates, either based on creatinine alone or creatinine plus cystatin C, are the most accurate for use in adults with HIV on stable ART [<a href="#rid60">60,62</a>], while the Cockcroft-Gault creatinine clearance remains the standard of care for drug dosing. CKD is identified by the presence of proteinuria or by an eGFR less than 60 mL/min per 1.73 m<sup>2</sup> for at least three months. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a> and  <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">"Definition and staging of chronic kidney disease in adults"</a>.)</p><p>Detailed discussions of monitoring patients with HIV are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3745.html" rel="external">"Primary care of adults with HIV", section on 'Hematologic, renal, and hepatic toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy", section on 'ART-associated toxicity'</a>.)</p><p></p><p>Identification of CKD in a patient with HIV should prompt initiation of ART (if not already started) and tight control of comorbid diabetes and hypertension (if present). Medication doses should be adjusted for the calculated creatinine clearance, with particular attention to nucleoside and nucleotide reverse transcriptase inhibitors. (See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p>Patients with HIV who have CKD should have at least biannual monitoring of eGFR, with medication dose adjustments as needed. The frequency of monitoring should be increased in patients with mildly reduced eGFR (ie, less than 90 mL/min per 1.73 m<sup>2</sup>) who are taking medications that have potential nephrotoxic effects, including the nucleotide analog tenofovir and boosted protease inhibitors [<a href="#rid24">24,25</a>].</p><p>Early referral to a nephrologist is important to coordinate diagnosis and treatment of CKD in patients with HIV, including discussion of the need for dialysis and the timely placement of dialysis access in patients with progressive disease [<a href="#rid24">24,25</a>]. Analyses of data from the United States Renal Data System (USRDS) have demonstrated similar outcomes in ESKD patients with HIV treated with hemodialysis or peritoneal dialysis, as well as significant improvements in survival in the ART era. (See  <a class="medical medical_review" href="/z/d/html/1915.html" rel="external">"Human immunodeficiency virus and dialysis"</a>.)</p><p>Kidney transplantation is a safe alternative in patients with preserved immune function and undetectable viral load. Based on promising results from South Africa, several transplant centers in the United States are now investigating the safety of kidney transplantation from donors with HIV [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/7332.html" rel="external">"Kidney transplantation in adults: Kidney transplantation in patients with HIV"</a>.)</p><p class="headingAnchor" id="H15534424"><span class="h1">ELECTROLYTE DISORDERS</span><span class="headingEndMark"> — </span>A variety of electrolyte disorders can occur in patients with HIV, which may be due to HIV-associated complications or medications used to treat HIV or its complications. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2375.html" rel="external">"Electrolyte disturbances with HIV infection"</a>.)</p><p class="headingAnchor" id="H1476875788"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H15534534"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV are at risk for both acute kidney injury (AKI) and chronic kidney disease (CKD) secondary to medication nephrotoxicity, HIV-associated nephropathy (HIVAN), and immune complex kidney diseases. In addition, the aging cohort of patients with HIV may be at increased risk for kidney disease related to hepatitis B virus (HBV) or hepatitis C virus (HCV) coinfection and comorbid or treatment-related diabetes and hypertension. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of AKI in patients with HIV is higher than it is in patients without HIV. Some risk factors for AKI among patients with HIV are similar to risk factors for AKI in the general population, such as older age, diabetes mellitus, preexisting CKD, and acute or chronic liver disease. However, some risk factors are specific to HIV. As in the general population, the development of AKI increases the risk morbidity and mortality in patients with HIV. (See <a class="local">'Epidemiology of AKI in patients with HIV'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common types of AKI in patients with HIV are prerenal states and acute tubular necrosis, although other etiologies may also occur. (See <a class="local">'Causes of AKI in patients with HIV'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV infection are at risk for nephrotoxicity from antiretroviral therapy (ART), as well as from medications used to treat opportunistic infections or hepatitis virus coinfection. Some of the more commonly implicated agents include the following (see <a class="local">'Medication nephrotoxicity'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protease inhibitors, such as <a class="drug drug_general" data-topicid="8558" href="/z/d/drug information/8558.html" rel="external">indinavir</a> and <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a>, can cause crystalluria and AKI. Use of some ritonavir-boosted protease inhibitors has also been associated with an increased risk of CKD. The newer protease inhibitor <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a> has not been associated with kidney disease risk.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">Tenofovir disoproxil fumarate</a> (TDF), a nucleoside reverse transcriptase inhibitor, can cause AKI with or without proximal tubular dysfunction. The newer prodrug <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> may be associated with a lower risk of kidney injury.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drugs used to treat opportunistic infections, including the antiviral agents <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">foscarnet</a>, and <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>, and the anti-<em>Pneumocystis</em> drugs <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> and <a class="drug drug_general" data-topicid="9752" href="/z/d/drug information/9752.html" rel="external">pentamidine</a>, can cause AKI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence and incidence of HIV-related CKD and end-stage kidney disease (ESKD) have decreased with the widespread use of ART but remain higher than in the general population. The etiology of CKD in patients with HIV includes traditional causes of CKD (such as hypertension, diabetes, and incomplete recovery from an episode of AKI) and HIV-related disorders (such as HIVAN and immune complex kidney disease in the setting of HIV). (See <a class="local">'Epidemiology of CKD in patients with HIV'</a> above and <a class="local">'Causes of CKD in patients with HIV'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with HIV should be screened for proteinuria and reduced glomerular filtration rate (GFR). Identification of CKD in a patient with HIV should prompt nephrology referral and initiation of ART. Medication doses should be adjusted for the level of GFR, with particular attention to nucleoside and nucleotide reverse transcriptase inhibitors. Patients with CKD should have at least biannual monitoring of estimated GFR (eGFR), with medication dose adjustments as needed. The frequency of monitoring should be increased in patients who are taking medications that have potential nephrotoxic effects, including the nucleotide analog, <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a>, and some boosted protease inhibitors. (See <a class="local">'Diagnosis and management of CKD in patients with HIV'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A variety of electrolyte disorders can occur in patients with HIV, which may be due to HIV-associated complications or medications used to treat HIV or its complications. (See  <a class="medical medical_review" href="/z/d/html/2375.html" rel="external">"Electrolyte disturbances with HIV infection"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29:378.</a></li><li><a class="nounderline abstract_t">Gardenswartz MH, Lerner CW, Seligson GR, et al. Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 1984; 21:197.</a></li><li><a class="nounderline abstract_t">Pardo V, Aldana M, Colton RM, et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:429.</a></li><li><a class="nounderline abstract_t">Rao TK, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:669.</a></li><li><a class="nounderline abstract_t">D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998; 18:406.</a></li><li><a class="nounderline abstract_t">Casanova S, Mazzucco G, Barbiano di Belgiojoso G, et al. Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study. Am J Kidney Dis 1995; 26:446.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. HIV-associated immune-mediated renal disease. Kidney Int 1993; 44:1327.</a></li><li><a class="nounderline abstract_t">Balow JE. Nephropathy in the context of HIV infection. Kidney Int 2005; 67:1632.</a></li><li><a class="nounderline abstract_t">Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327:702.</a></li><li><a class="nounderline abstract_t">Stokes MB, Chawla H, Brody RI, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis 1997; 29:514.</a></li><li><a class="nounderline abstract_t">Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324:1457.</a></li><li><a class="nounderline abstract_t">Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20:561.</a></li><li><a class="nounderline abstract_t">Li Y, Shlipak MG, Grunfeld C, Choi AI. Incidence and risk factors for acute kidney injury in HIV Infection. Am J Nephrol 2012; 35:327.</a></li><li><a class="nounderline abstract_t">Nadkarni GN, Patel AA, Yacoub R, et al. The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis. AIDS 2015; 29:1061.</a></li><li><a class="nounderline abstract_t">Franceschini N, Napravnik S, Eron JJ Jr, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67:1526.</a></li><li><a class="nounderline abstract_t">Roe J, Campbell LJ, Ibrahim F, et al. HIV care and the incidence of acute renal failure. Clin Infect Dis 2008; 47:242.</a></li><li><a class="nounderline abstract_t">Choi AI, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int 2010; 78:478.</a></li><li><a class="nounderline abstract_t">Peraldi MN, Maslo C, Akposso K, et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol Dial Transplant 1999; 14:1578.</a></li><li><a class="nounderline abstract_t">Rao TK, Friedman EA. Outcome of severe acute renal failure in patients with acquired immunodeficiency syndrome. Am J Kidney Dis 1995; 25:390.</a></li><li><a class="nounderline abstract_t">Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667.</a></li><li><a class="nounderline abstract_t">Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867.</a></li><li><a class="nounderline abstract_t">Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 2013; 207:1359.</a></li><li><a class="nounderline abstract_t">Wyatt CM, Kitch D, Gupta SK, et al. Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr 2014; 67:36.</a></li><li><a class="nounderline abstract_t">Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.</a></li><li><a class="nounderline abstract_t">Swanepoel CR, Atta MG, D'Agati VD, et al. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2018; 93:545.</a></li><li><a class="nounderline abstract_t">Wikman P, Safont P, Del Palacio M, et al. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. Nephrol Dial Transplant 2013; 28:2073.</a></li><li><a class="nounderline abstract_t">Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273.</a></li><li><a class="nounderline abstract_t">Zaidan M, Lescure FX, Brochériou I, et al. Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study. Clin J Am Soc Nephrol 2013; 8:930.</a></li><li><a class="nounderline abstract_t">Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385:2606.</a></li><li><a class="nounderline abstract_t">Novick TK, Choi MJ, Rosenberg AZ, et al. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report. Medicine (Baltimore) 2017; 96:e8046.</a></li><li><a class="nounderline abstract_t">Serota DP, Franch HA, Cartwright EJ. Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection. Open Forum Infect Dis 2018; 5:ofy189.</a></li><li><a class="nounderline abstract_t">Ryom L, Dilling Lundgren J, Reiss P, et al. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 2019; 220:1629.</a></li><li><a class="nounderline abstract_t">Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16:2412.</a></li><li><a class="nounderline abstract_t">Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61:195.</a></li><li><a class="nounderline abstract_t">Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203.</a></li><li><a class="nounderline abstract_t">German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61:32.</a></li><li><a class="nounderline abstract_t">Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75:990.</a></li><li><a class="nounderline abstract_t">Boccia RV, Gelmann EP, Baker CC, et al. A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:716.</a></li><li><a class="nounderline abstract_t">Bachmeyer C, Blanche P, Séréni D, et al. Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in HIV-infected patients. AIDS 1995; 9:532.</a></li><li><a class="nounderline abstract_t">Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39 Suppl 5:S267.</a></li><li><a class="nounderline abstract_t">Razzak Chaudhary S, Workeneh BT, Montez-Rath ME, et al. Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrol Dial Transplant 2015; 30:1734.</a></li><li><a class="nounderline abstract_t">Jotwani V, Li Y, Grunfeld C, et al. Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors. Am J Kidney Dis 2012; 59:628.</a></li><li><a class="nounderline abstract_t">Estrella MM, Parekh RS, Astor BC, et al. Chronic kidney disease and estimates of kidney function in HIV infection: a cross-sectional study in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2011; 57:380.</a></li><li><a class="nounderline abstract_t">Cailhol J, Nkurunziza B, Izzedine H, et al. Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study. BMC Nephrol 2011; 12:40.</a></li><li><a class="nounderline abstract_t">Emem CP, Arogundade F, Sanusi A, et al. Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors. Nephrol Dial Transplant 2008; 23:741.</a></li><li><a class="nounderline abstract_t">Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129.</a></li><li><a class="nounderline abstract_t">Achhra AC, Mocroft A, Ross MJ, et al. Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 Suppl 1:55.</a></li><li><a class="nounderline abstract_t">Peters L, Grint D, Lundgren JD, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS 2012; 26:1917.</a></li><li><a class="nounderline abstract_t">Mocroft A, Neuhaus J, Peters L, et al. Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 2012; 7:e40245.</a></li><li><a class="nounderline abstract_t">Lucas GM, Jing Y, Sulkowski M, et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013; 208:1240.</a></li><li><a class="nounderline abstract_t">Kalayjian RC, Lau B, Mechekano RN, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 2012; 26:1907.</a></li><li><a class="nounderline abstract_t">Scherzer R, Gandhi M, Estrella MM, et al. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans. AIDS 2014; 28:1289.</a></li><li><a class="nounderline abstract_t">Mocroft A, Lundgren JD, Ross M, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med 2015; 12:e1001809.</a></li><li><a class="nounderline abstract_t">Kudose S, Santoriello D, Bomback AS, et al. The spectrum of kidney biopsy findings in HIV-infected patients in the modern era. Kidney Int 2020; 97:1006.</a></li><li><a class="nounderline abstract_t">Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int 2006; 69:1885.</a></li><li><a class="nounderline abstract_t">Katz A, Bargman JM, Miller DC, et al. IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy? Clin Nephrol 1992; 38:61.</a></li><li><a class="nounderline abstract_t">Foy MC, Estrella MM, Lucas GM, et al. Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy. Clin J Am Soc Nephrol 2013; 8:1524.</a></li><li><a class="nounderline abstract_t">Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145.</a></li><li><a class="nounderline abstract_t">Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases. Kidney Int 2005; 67:1381.</a></li><li><a class="nounderline abstract_t">Inker LA, Wyatt C, Creamer R, et al. Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals. J Acquir Immune Defic Syndr 2012; 61:302.</a></li><li><a class="nounderline abstract_t">Bhasin B, Lau B, Atta MG, et al. HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C. PLoS One 2013; 8:e82028.</a></li><li><a class="nounderline abstract_t">Vrouenraets SM, Fux CA, Wit FW, et al. A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. Clin Nephrol 2012; 77:311.</a></li><li><a class="nounderline abstract_t">Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. N Engl J Med 2015; 372:613.</a></li></ol></div><div id="topicVersionRevision">Topic 14027 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11917243" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6733986" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Renal disease in patients with AIDS: a clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6476632" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Glomerular lesions in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700641" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692353" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Renal pathology of human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645552" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8301934" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : HIV-associated immune-mediated renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780122" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nephropathy in the context of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1495523" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100039" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2023605" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Membranous nephropathy related to hepatitis B virus in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16470120" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22456100" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence and risk factors for acute kidney injury in HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26125139" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780107" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence and etiology of acute renal failure among ambulatory HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18540821" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HIV care and the incidence of acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20520594" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term clinical consequences of acute kidney injury in the HIV-infected.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383033" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872316" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Outcome of severe acute renal failure in patients with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523203" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22313955" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of tenofovir exposure with kidney disease risk in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23382571" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25117929" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15889353" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398134" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23739150" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545703" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430209" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25890673" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28885375" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30151414" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504669" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987747" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786101" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Predictors of proteinuria and renal failure among women with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594796" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22732469" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22905856" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486607" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639985" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494898" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26175146" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22206742" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21646913" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chronic kidney disease and estimates of kidney function in HIV infection: a cross-sectional study in the multicenter AIDS cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21864389" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18065807" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Renal disease in HIV-seropositive patients in Nigeria: an assessment of prevalence, clinical features and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21997394" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25711324" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22781222" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911697" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23904290" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22824630" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24922479" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25826420" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32278618" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The spectrum of kidney biopsy findings in HIV-infected patients in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625149" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : HIV-related nephropathy: a South African perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516281" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685946" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of risk factors and outcomes in HIV immune complex kidney disease and HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327410" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780090" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22842844" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24376511" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22445475" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671253" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
